HM
RAPT

HealthCor Management’s RAPT Therapeutics RAPT Stock Holding History

HealthCor Management’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-27,146
Closed -$3.96M – 68
2022
Q2 		$3.96M Sell
27,146
-5,873
-18% -$783K 0.4% 40
2022
Q1 		$5.81M Buy
33,019
+10,344
+46% +$1.95M 0.39% 44
2021
Q4 		$6.66M Sell
22,675
-413
-2% -$110K 0.36% 46
2021
Q3 		$5.74M Sell
23,088
-1,912
-8% -$505K 0.25% 46
2021
Q2 		$6.36M Buy
+25,000
New +$4.67M 0.25% 48

Other funds holding RAPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

HealthCor Management's RAPT Position: Q3 2022 in Review

HealthCor Management sold out of RAPT Therapeutics (RAPT) in Q3 2022, closing a stake of 27,146 shares — an estimated $3.96M sold.

HealthCor Management first reported a position in RAPT in Q2 2021 and held it in 5 quarters. The position peaked at $6.66M in Q4 2021. 98 funds tracked by Wall St. Rank hold RAPT as of Q3 2022.

  • HealthCor Management reported no remaining RAPT Therapeutics position as of Q3 2022 after selling out during the quarter.
  • HealthCor Management sold 27,146 RAPT Therapeutics shares in Q3 2022, an estimated $3.96M.
  • HealthCor Management first reported a position in RAPT Therapeutics in Q2 2021 and held it in 5 quarters.
  • HealthCor Management's RAPT Therapeutics position peaked at $6.66M in Q4 2021.
  • 98 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q3 2022.

Based on HealthCor Management's 13F filing for Q3 2022, filed 14 Nov 2022.